Abstract:Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disease with left ventricular hypertrophy, myocardial hypercontraction, cardiomyocyte disturbance, and fibrosis. [ 1 ] It is one of the most critical reasons behind sudden cardiac death in children and adolescents. [ 2 ] Echocardiography shows that the incidence of HCM in adults is estimated to be 0.2%, [ 3 ] and considering the clinical and genetic characteristics (including the patient family members), the prevalence reaches 0.5%. [ 4 ] However, the pathophysiology of HCM is complex, and the clinical manifestations and prognosis are diverse, warranting successful diagnosis only when the cardiac morphology changes and function failure worsens. In addition, drug-mediated and surgical therapies are the most important treatment methods for HCM. However, these methods primarily play a role in reducing clinical symptoms, and to date, treatment plans for the subsequent developmental stages of the disease are lacking. Currently, the signaling pathways and regulatory networks underlying the pathogenesis of HCM are yet to be fully understood. [ 5 , 6 ] Therefore, more in-depth exploration and identification of potential genes and biological pathways underlying the pathogenesis of HCM is crucial for diagnosis and treatment.

Identification and validation of pyroptosis-related genes as potential biomarkers for hypertrophic cardiomyopathy: A comprehensive bioinformatics analysis